The Combating Illicit Xylazine Act places xylazine - a veterinary sedative increasingly found in illicit drug mixtures - into Schedule III of the Controlled Substances Act, subjecting it to federal regulation as a controlled substance. It specifically allows veterinary use without requiring registration of the ultimate user (e.g., pet owners or veterinarians) if xylazine is dispensed by a registered veterinarian or pharmacy with a vet prescription and used for animals owned by the user, under their care, or in authorized animal programs. The bill provides a one-year delay for labeling and packaging requirements and a 60-day delay for registration and recordkeeping for veterinary use to ease implementation. Additionally, it adds xylazine to the Arcos tracking system for controlled substances and mandates two congressional reports on illicit use prevalence within 18 months and 4 years of enactment.
Preserving Patient Access to Home Infusion Act This bill specifically includes pharmacy services and home infusion drugs that are administered without a pump as part of covered home infusion therapy under Medicare. The bill also allows nurses and physician assistants to establish and review the plan of care for home infusion therapy, and it specifies that payment may be made regardless of whether a practitioner is physically present in the home at the time the drug is administered.
This bill exempts certain orally administered drugs from Medicare Part D's manufacturer discount program. Specifically, it excludes drugs that: (1) received FDA approval under the standard new drug application process, and (2) have been granted a narrow CMS exception allowing them to be treated as noninnovator drugs under Medicaid rebates. The exemption applies directly to these specific drugs meeting both criteria, altering how their costs are calculated under Medicare Part D. This change affects drug manufacturers and Medicare beneficiaries by modifying the discount structure for these particular medications.
The Fair Prescription Drug Prices for Americans Act would cap the U.S. list price for prescription drugs and biological products at the average price in Canada, France, Germany, Italy, Japan, and the United Kingdom. Drug manufacturers must annually report U.S. and international prices to the Health and Human Services Secretary, who calculates the six-country average. If a U.S. price exceeds this average, manufacturers face a civil penalty of 10 times the price difference per unit sold. The bill directly targets drug pricing practices without altering drug approval processes or insurance coverage.
This bill, S 641 (Safe and Affordable Drugs from Canada Act of 2025), would allow U.S. individuals to import certain prescription drugs from Canada under specific conditions. It requires drugs to come from FDA-certified Canadian pharmacies, match U.S.-approved drugs in active ingredients and form, be for personal use (not resale) in 90-day quantities, and include a U.S. physician's prescription. The bill excludes controlled substances, biologics, infused drugs, and other high-risk medications. It directly affects U.S. patients seeking lower-cost prescriptions who meet these criteria. The FDA would establish the certification process for Canadian pharmacies within 180 days of enactment.
The HELP Copays Act requires that financial assistance from non-profit organizations or prescription drug manufacturers counts toward patients' annual out-of-pocket cost-sharing limits (like deductibles and copays) for certain prescription drugs. It directly affects individuals enrolled in group health plans or individual insurance who receive such assistance, ensuring payments from these sources reduce their total out-of-pocket spending. The bill amends key healthcare laws to include these payments in calculating cost-sharing thresholds, specifically for specialty drugs and drugs subject to utilization management (like prior authorization). It takes effect for plan years beginning in 2026 and does not change how utilization management tools are applied.
HR 2553, the Capping Prescription Costs Act of 2025, limits out-of-pocket costs for prescription drugs under health insurance. It sets a $2,000 annual cap per individual or $4,000 per family for covered prescriptions starting in 2026, with annual adjustments based on the medical care CPI. The bill applies directly to people with employer-sponsored group health plans, individual health insurance plans, and plans covered under the Affordable Care Act. It requires insurers and plan sponsors to ensure cost-sharing for prescriptions does not exceed these limits, effective for plan years beginning January 1, 2026.
HR 7391, the Community Health Center Drug Pricing Protection Act, requires that Federally Qualified Health Centers (FQHCs) pay the discounted 340B ceiling price for covered drugs **at the time of purchase**, not later through rebates or adjustments. This directly affects FQHCs, which rely on 340B discounts to provide affordable care to low-income patients. The bill amends the Public Health Service Act to prohibit manufacturers from entering agreements where FQHCs initially pay more than the ceiling price, with later reimbursement. It takes effect immediately upon enactment for all new drug purchases and applies to existing agreements starting then.
The 340B PATIENTS Act of 2025 clarifies that drug manufacturers must offer discounted prices under the 340B program to covered entities - such as community health centers, hospitals, and clinics - regardless of how or where drugs are dispensed, including through contracted pharmacies. It prohibits manufacturers from imposing restrictions on covered entities, such as limiting delivery locations, requiring extra data, or restricting how discounted drugs are used. The bill also establishes civil penalties for violations, including daily fines of up to $2 million, and allows covered entities to file claims for breaches of these rules. This ensures that covered entities can continue using contract pharmacies to access specialty drugs for patients with chronic or serious conditions.
This bill targets pharmaceutical companies that extend patent protection for the same drug through multiple overlapping patents, a practice sometimes called "evergreening." It creates a presumption that companies must disclaim patent term for subsequent patents covering the same drug after the first patent expires, unless they prove the patents cover truly distinct inventions. The bill also requires the U.S. Patent Office to review its processes to prevent issuing such overlapping patents and report findings within a year. This directly affects pharmaceutical companies holding multiple patents for single drugs and aims to reduce artificial extensions of drug exclusivity, potentially lowering costs for consumers and insurers.
